These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32122256)

  • 1. Efficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials.
    Chang CH; Lin CH; Liu CY; Chen SJ; Lane HY
    J Psychopharmacol; 2020 May; 34(5):495-505. PubMed ID: 32122256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of N-methyl-D-aspartate-receptor-enhancing agents on cognition in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials.
    Chang CH; Lane HY; Tseng PT; Chen SJ; Liu CY; Lin CH
    J Psychopharmacol; 2019 Apr; 33(4):436-448. PubMed ID: 30730250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.
    Singh SP; Singh V
    CNS Drugs; 2011 Oct; 25(10):859-85. PubMed ID: 21936588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial.
    Lin CY; Liang SY; Chang YC; Ting SY; Kao CL; Wu YH; Tsai GE; Lane HY
    World J Biol Psychiatry; 2017 Aug; 18(5):357-368. PubMed ID: 26691576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
    Tsai G; Lane HY; Yang P; Chong MY; Lange N
    Biol Psychiatry; 2004 Mar; 55(5):452-6. PubMed ID: 15023571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sarcosine as an add-on treatment to antipsychotic medication for people with schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
    Marchi M; Galli G; Magarini FM; Mattei G; Galeazzi GM
    Expert Opin Drug Metab Toxicol; 2021 Apr; 17(4):483-493. PubMed ID: 33538213
    [No Abstract]   [Full Text] [Related]  

  • 7. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.
    Lane HY; Huang CL; Wu PL; Liu YC; Chang YC; Lin PY; Chen PW; Tsai G
    Biol Psychiatry; 2006 Sep; 60(6):645-9. PubMed ID: 16780811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modafinil for people with schizophrenia or related disorders.
    Ortiz-Orendain J; Covarrubias-Castillo SA; Vazquez-Alvarez AO; Castiello-de Obeso S; Arias Quiñones GE; Seegers M; Colunga-Lozano LE
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD008661. PubMed ID: 31828767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia.
    Lane HY; Lin CH; Huang YJ; Liao CH; Chang YC; Tsai GE
    Int J Neuropsychopharmacol; 2010 May; 13(4):451-60. PubMed ID: 19887019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
    Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
    Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.
    Barber S; Olotu U; Corsi M; Cipriani A
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD006324. PubMed ID: 28333365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Supplementation of antipsychotic treatment with sarcosine – GlyT1 inhibitor – causes changes of glutamatergic (1)NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia.
    Strzelecki D; Podgórski M; Kałużyńska O; Gawlik-Kotelnicka O; Stefańczyk L; Kotlicka-Antczak M; Gmitrowicz A; Grzelak P
    Neurosci Lett; 2015 Oct; 606():7-12. PubMed ID: 26306650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of
    Goh KK; Wu TH; Chen CH; Lu ML
    J Psychopharmacol; 2021 Mar; 35(3):236-252. PubMed ID: 33406959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycine transporter-1: a new potential therapeutic target for schizophrenia.
    Hashimoto K
    Curr Pharm Des; 2011; 17(2):112-20. PubMed ID: 21355838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders.
    Dold M; Samara MT; Li C; Tardy M; Leucht S
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD009831. PubMed ID: 25592299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of glycine transporter I inhibitor, N-methylglycine (sarcosine), on ketamine-induced alterations in sensorimotor gating and regional brain c-Fos expression in rats.
    Yang SY; Hong CJ; Huang YH; Tsai SJ
    Neurosci Lett; 2010 Jan; 469(1):127-30. PubMed ID: 19944746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential and underlying mechanism of sarcosine (N-methylglycine) in N-methyl-D-aspartate (NMDA) receptor hypofunction models of schizophrenia.
    Pei JC; Hung WL; Lin BX; Shih MH; Lu LY; Luo DZ; Tai HC; Studer V; Min MY; Lai WS
    J Psychopharmacol; 2019 Oct; 33(10):1288-1302. PubMed ID: 31294644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site.
    Shim SS; Hammonds MD; Kee BS
    Eur Arch Psychiatry Clin Neurosci; 2008 Feb; 258(1):16-27. PubMed ID: 17901997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in the preparation and testing of glycine transporter type-1 (GlyT1) inhibitors.
    Lindsley CW; Wolkenberg SE; Kinney GG
    Curr Top Med Chem; 2006; 6(17):1883-96. PubMed ID: 17017963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Repetitive Transcranial Magnetic Stimulation in Patients With Methamphetamine Use Disorder: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials.
    Chang CH; Liou MF; Liu CY; Lu WH; Chen SJ
    Front Psychiatry; 2022; 13():904252. PubMed ID: 35711590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.